NH Hospital's innovative approach to mental health is based on the patient's biochemical makeup and gene-environment interfaces. Photo courtesy of NH Hospital

There's no one-size-fits-all solution to medical care. NH Hospital is bringing innovative technologies and functional medicine to patients in the Houston area. Using patients' biochemical makeup, the medical provider has created a unique service for Houstonians seeking a multi-pronged approach to behavioral health and substance use disorders.

The past year has been an incubator for mental health issues. Pandemic isolation, social distancing, financial instability, racial reckonings, and a massive death toll have posed an enormous threat to the mental wellbeing of people around the world. Experts predict a long-term spike in post-traumatic stress disorder (PTSD) cases as society grapples with the tragedies of the last year, but the toll is already here.

A recent Centers for Disease Control and Prevention (CDC) study found that the percentage of adults with recent symptoms of anxiety or depression increased from 36.4 to 41.5 percent between Aug. 19, 2020, and Feb. 1, 2021.

As the world waits for a moment to exhale after a catastrophic year, NH Hospital keeps busy serving patients struggling with both behavioral health and addiction during the pandemic. Outside of depression and anxiety, the facility also treats bipolar disorder, PTSD, codependency, and postpartum depression by using a multidisciplinary approach.

NH Hospital integrates traditional medicine with functional medicine with a mission of treating the root cause of an issue and not just the symptoms. From providing an on-site chef and nutritionist to stimulating patients with calming acoustic therapy, the facility blends unique treatment modalities that address the whole body rather than an isolated issue.

"With functional medicine, we find other avenues and ways to allow [patients] to heal and to change their behavior," explains Debbie Cormier, CEO of NH Hospital.

Using genetic markers as a roadmap to health

You can build the closet of Carrie Bradshaw's dreams online, buy bespoke cologne based on your body chemistry, monogram jewelry and clothing, and even get a Renaissance-style portrait of your family pet. Tailor-made options are ubiquitous; why not customize medical care?

"For years, the traditional way, we just gave people the same amount of meds, the same diets, the same everything," and wondered why some patients responded better or quicker than others, explains Cormier. For the unlucky patients who didn't get stellar results, she says doctors may have thought "they just have to deal with it" and wait. "We don't feel that you should have to just deal with it," she continues.

When treating a patient, NH Hospital doctors consider the genetic makeup of each patient to create a custom care plan. With tests as simple as a swab of the cheek, the facility can gather biochemical markers that can share valuable medical information like risk factors for diseases.

Cormier believes NH Hospital's ability to look at a patient's genetic background and "treat you as an individual," is a key factor that sets the facility apart. The hospital also focuses on understanding how your genes interact with your environment.

Think of gene-environment interactions as nature vs. nurture, an ideology that research suggests plays significant roles in the outset of mental illness. Genetic and environmental factors interact to influence phenotype, the observable characteristics you exhibit when your genotype and environment interact.

When these factors are off-balance, it can result in undesirable results. A 2001 study of Finnish twins studied the socio-geographic impact on adolescent alcohol use in urban and rural environments. While the frequency of alcohol use was the same in both settings, the factors that led adolescents to drink were entirely different. Genetic factors played a larger role in urban areas, whereas the shared environment had a greater influence in rural settings.

By applying various modalities based on genetic information, doctors aren't going in blind and "know you from the inside out," says Cormier.

When a patient comes in struggling with something as grappling as depression or anxiety, conditions they've seen an uptick in since the beginning of the pandemic, doctors will run a genetic test as well as traditional lab work. Cormier says some potential treatment paths may include photosynthesis therapy, hydration therapy and nutrition.

Dietetics meets tech

NH Hospital helps patients get micronutrient infusions, but its nutrition program provides an integrated approach to fueling the body with the help of a staff chef.

"We only have so much energy every day, and we choose how we use the energy but by getting your diet right, it starts to heal you in all kinds of ways," says Cormier.

While the physical repercussions of a poor diet like diabetes and heart disease are widely known, you may be surprised to hear that nutrition can affect mood disorders and harm brain cells. According to Harvard Health Publishing, refined sugars can lead to brain impairment, depression and oxidative stress — the free radicals produced when the body uses oxygen, which can damage cells. By focusing on a patient's nutrition, "the person has a better chance to heal, not only from the issue that is brought to us but to overall feel good," she says.

Counseling, cryotherapy, transcranial magnetic stimulation and cocoon therapy therapies are just some of the other methods NH Hospital doctors use to treat their patients.

Cormier recalls the recovery of a patient who was experiencing depression and using a wheelchair due to pain in her knees. She gradually gained the ability to walk without pain again after a months-long treatment plan of cryotherapy and micronutrient infusions.

"She said that we really changed her life because we gave her back her life. Now she's walking a mile a day around her block and she's able to do daily moving. She said she hadn't done that in years," says Cormier.

A mission to heal

Outside of neuropsychology, NH Hospital offers medical detox with monitoring from trained professionals and therapy plans for patients coming off of alcohol, methamphetamine, heroin, opioids like fentanyl and other prescription drugs.

Since the U.S. The Department of Health and Human Services declared the opioid epidemic as a public health emergency in 2017, nearly 841,000 people have died of an opioid overdose. Like anxiety and depression, addiction is also on the rise during the pandemic. A CDC survey found that 13 percent of respondents began using drugs during the pandemic or increased their use of illicit substances.

NH Hospital doctors provide micronutrients among other aides to help "build [patients] up] before taking them off the drugs, says Cormier. "We're just trying to make sure the patient feels safe and that if we're doing all these things, we continue to move them in a positive direction instead of just letting them sweat it out," she says.

"Our leadership here is committed to doing what it takes to help people whether they have behavioral, medical, or whatever [condition] brings them through our doors so that we make them have a better life," says Cormier.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”